康恩贝品牌怎么样 申请店铺

我要投票 康恩贝在牛初乳行业中的票数:6 更新时间:2024-11-23
康恩贝是哪个国家的品牌?「康恩贝」是 浙江康恩贝制药股份有限公司 旗下著名品牌。该品牌发源于浙江,由创始人胡季强在1993-01-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
康恩贝怎么样


浙江康恩贝制药股份有限公司是康恩贝集团有限公司的控股子公司,是一家集药材种植及药品研发、生产、销售为一体的医药上市企业。公司的前身为创建于1969年的“兰溪云山制药厂”,1990年更名为“浙江康恩贝制药公司”;1992年6月5日,经浙江省股份制试点工作协调小组批准,浙江康恩贝制药公司改组为“浙江康恩贝股份有限公司”;1999年10月,公司正式更名为“浙江康恩贝制药股份有限公司”。

公司注册地为兰溪,管理总部设在浙江省杭州市,公司在杭州、兰溪、金华,以及江西、云南、内蒙古、四川等地拥有先进规范的药品生产基地,并在兰溪建有国内最大的现代植物药制造基地——康恩贝植物药产业园。公司旗下拥有浙江康恩贝中药有限公司、浙江金华康恩贝生物制药有限公司、云南希陶绿色药业股份有限公司、杭州康恩贝制药有限公司、江西天施康中药股份有限公司、浙江康恩贝药品研究开发有限公司、浙江康恩贝医药销售有限公司、上海康恩贝医药有限公司、云南康恩贝植物药有限公司、内蒙古康恩贝药业有限公司等多个颇具规模和实力的全资及控股子公司。

公司为国家火炬计划重点高新技术企业、国家创新型企业、国家知识产权试点企业、国家中药二十强企业、科技部中药现代化科技产业基地先进单位、浙江省“五个一批”重点骨干企业、浙江省重点企业研究院、浙江省专利示范企业、浙江省创新型示范企业,建有国家认定企业技术中心、国家博士后科研工作站、院士工作站、浙江省中药制药技术重点实验室、省级研发中心和技术中心,是浙江省首批重点企业技术创新团队。

公司拥有一支由博士、硕士和高、中级职称的技术人员组成的实力雄厚、专注于现代植物药和特色化学药研发的团队,与国内外知名科研机构、大专院校建立了长期的战略合作伙伴和战略联盟,已建立新药研发的多个技术平台,通过聘请行业权威人士组成研发专家委员会,在心脑血管系统用药、泌尿系统用药、抗糖尿病用药、呼吸道系统用药、消化系统用药和抗感染药等药物的研发,以及植物提取分离和结构改造、新型药物释放系统应用等诸多方面,以现代植物药、特色化学药发展为主线,研发具有自主知识产权的新药,在药材种植、原料药和植物提取、新药研发、制剂生产、市场营销等各环节,已建立起规范高效的产业体系。

公司历来十分重视产品品牌和企业品牌的培育和保护,在泌尿系统及心脑血管系统等多个领域建立了消费者熟知与认可的品牌,如今,公司已成为浙江省拥有著名商标和名牌产品最多的企业之一。其中,“康恩贝”、“前列康”、“珍视明”被认定为中国驰名商标,“阿乐欣”、“金康”、“金奥康”、“希陶”、“天保康”、“天狮”等均在各自领域拥有较高的品牌知名度,在同类竞争产品中已树立起了较突出的品牌优势。

展望未来,公司将继续秉承“集天下才智,创宏伟事业,为人类健康、献至诚至爱”的企业宗旨,恪守“诚实守信、依法经营,质量第一、顾客至上,安全第一、友好环境,关爱员工、奉献社会”的四大天条,倡导并培育公司和谐与激情并进的文化氛围,努力发挥公司整体实力和品牌优势,一如既往地致力于现代植物药领域的创新发展,将康恩贝打造成为中国最具品牌价值的医药企业和世界植物药领军企业!


Zhejiang Kangenbei Pharmaceutical Co., Ltd. is a holding subsidiary of Kangenbei Group Co., Ltd. It is a pharmaceutical listed enterprise integrating the cultivation of medicinal materials, drug research and development, production and sales. The predecessor of the company is "Lanxi Yunshan pharmaceutical factory" founded in 1969, renamed as "Zhejiang Kangenbei pharmaceutical company" in 1990; on June 5, 1992, Zhejiang Kangenbei pharmaceutical company was reorganized as "Zhejiang Kangenbei Co., Ltd." with the approval of Zhejiang joint stock pilot work coordination group; in October 1999, the company was officially renamed as "Zhejiang Kangenbei Pharmaceutical Co., Ltd." " The company is registered in Lanxi, with its management headquarters in Hangzhou, Zhejiang Province. The company has advanced and standardized drug production bases in Hangzhou, Lanxi, Jinhua, Jiangxi, Yunnan, Inner Mongolia, Sichuan and other places. In Lanxi, it has the largest modern plant drug manufacturing base in China, Kangenbei plant drug Industrial Park. The company has Zhejiang kangenbe traditional Chinese Medicine Co., Ltd., Zhejiang Jinhua kangenbe Biological Pharmaceutical Co., Ltd., Yunnan Xitao green Pharmaceutical Co., Ltd., Hangzhou kangenbe Pharmaceutical Co., Ltd., Jiangxi tianshikang traditional Chinese Medicine Co., Ltd., Zhejiang kangenbe pharmaceutical research and Development Co., Ltd., Zhejiang kangenbe Pharmaceutical Sales Co., Ltd., and Shanghai kangenbe Pharmaceutical Co., Ltd , Yunnan Kangenbei Plant Medicine Co., Ltd., Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. and many other wholly-owned and holding subsidiaries with considerable scale and strength. The company is a key high-tech enterprise of the national torch plan, a national innovative enterprise, a national intellectual property pilot enterprise, a top 20 enterprise of the national traditional Chinese medicine, an advanced unit of the modern science and technology industrial base of traditional Chinese medicine of the Ministry of science and technology, a "five batch" key backbone enterprise of Zhejiang Province, a Research Institute of key enterprises of Zhejiang Province, a patent demonstration enterprise of Zhejiang Province, and an innovative demonstration enterprise of Zhejiang Province The state recognized enterprise technology center, National Postdoctoral research workstation, academician workstation, Zhejiang Key Laboratory of traditional Chinese medicine pharmaceutical technology, provincial R & D center and technology center are the first batch of key enterprise technology innovation teams in Zhejiang Province. The company has a strong team composed of doctors, masters and technicians with senior and intermediate professional titles, focusing on the research and development of modern plant medicine and characteristic chemical medicine. It has established long-term strategic partners and strategic alliances with well-known scientific research institutions and colleges at home and abroad. It has established multiple technical platforms for new drug research and development, and hired industry authorities to form research and development experts The committee, in the research and development of cardiovascular and cerebrovascular system drugs, urinary system drugs, antidiabetic drugs, respiratory system drugs, digestive system drugs and anti infective drugs, as well as plant extraction and separation, structural transformation, application of new drug delivery system, etc., takes the development of modern plant drugs and characteristic chemicals as the main line, and develops new drugs with independent intellectual property rights, A standardized and efficient industrial system has been established in various links such as the cultivation of medicinal materials, the extraction of raw materials and plants, the research and development of new drugs, the production of preparations, and the marketing. The company has always attached great importance to the cultivation and protection of product brands and enterprise brands. It has established brands well known and recognized by consumers in many fields such as urinary system, cardiovascular and cerebrovascular system. Now, the company has become one of the most famous brands and famous brand products in Zhejiang Province. Among them, "Kangenbei", "QianLieKang" and "Zhenshiming" are recognized as well-known trademarks in China, "alexin", "Jinkang", "jinaokang", "Xitao", "Tianbaokang" and "Tianshi" all have high brand awareness in their respective fields, and have established prominent brand advantages in similar competitive products. Looking forward to the future, the company will continue to adhere to the enterprise tenet of "gathering the wisdom of the world, creating a grand cause, serving the health of mankind, offering sincere love", adhere to the four tenets of "honest and trustworthy, operating according to law, quality first, customer first, safety first, friendly environment, caring for employees and contributing to the society", advocate and cultivate a harmonious and passionate cultural atmosphere of the company, and strive to play The company's overall strength and brand advantage, as always, is committed to the innovation and development of modern botanical medicine field, and will build Kangenbei into the most famous pharmaceutical enterprise in China and the world's leading enterprise in botanical medicine!

本文链接: https://brand.waitui.com/34532c964.html 联系电话:057187774811

千城特选小程序码

7×24h 快讯

三六零:前三季度基于“360智脑”能力开发的互联网ToC端产品直接收入占整体营收不超2%

36氪获悉,三六零发布股票交易异常波动公告,公司于2024年10月31日披露了《三六零安全科技股份有限公司2024年第三季度报告》,2024年1-9月归属于母公司所有者的净利润为-5.79亿元。2024年前三季度,基于“360智脑”能力开发的互联网ToC端产品所产生的直接收入在整体营业收入占比不超过2%,对公司业绩不构成重大影响。

2小时前

小鹏MONA哨兵模式将于明年一季度上线

36氪获悉,小鹏汽车董事长何小鹏在微博发文,小鹏MONA即将于2025年第一季度推出哨兵模式。

2小时前

爱婴室:股东拟减持不超过1%公司股份

36氪获悉,爱婴室发布公告,股东莫锐强的一致行动人茂强投资、莫锐伟拟通过集中竞价交易方式合计减持公司股份不超过138.54万股(即不超过公司总股本的1%)。

2小时前

顺丰控股在香港上市据悉计划将价格定在区间中点

顺丰控股在香港上市据悉计划将价格定在区间中点。(财联社)

2小时前

欧洲央行副行长:降息路径比降息幅度更重要

欧洲央行副行长Luis de Guindos表示,央行显然在降息的道路上,但每次货币政策会议的降息幅度并没有那么重要。他补充说,明年薪资增长将放缓,并且欧洲央行预计通胀将向2%的目标靠拢。“如果我们对明年的通胀预测确实成为现实,那么货币政策路径是明确的,”他周五在马德里的一次会议上说。“我们是降息50个基点还是25个基点的问题就不那么重要了。”(新浪财经)

2小时前

本页详细列出关于康普生物KANPURE的品牌信息,含品牌所属公司介绍,康普生物KANPURE所处行业的品牌地位及优势。
咨询